Management of Chemotherapy-Induced Nausea and Vomiting New Agents and New Uses of Current Agents /

This book provides a comprehensive review of new agents, a detailed description of new uses of current agents, and an integration of the available agents in clinical practice. A description of a detailed clinical approach provides clinical practitioners with the most up-to-date recommendations for t...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Άλλοι συγγραφείς: Navari, Rudolph M. (Επιμελητής έκδοσης)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Cham : Springer International Publishing : Imprint: Adis, 2016.
Έκδοση:1st ed. 2016.
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 03993nam a22004695i 4500
001 978-3-319-27016-6
003 DE-He213
005 20160126151354.0
007 cr nn 008mamaa
008 160125s2016 gw | s |||| 0|eng d
020 |a 9783319270166  |9 978-3-319-27016-6 
024 7 |a 10.1007/978-3-319-27016-6  |2 doi 
040 |d GrThAP 
050 4 |a RC254-282 
072 7 |a MJCL  |2 bicssc 
072 7 |a MED062000  |2 bisacsh 
082 0 4 |a 616.994  |2 23 
245 1 0 |a Management of Chemotherapy-Induced Nausea and Vomiting  |h [electronic resource] :  |b New Agents and New Uses of Current Agents /  |c edited by Rudolph M. Navari. 
250 |a 1st ed. 2016. 
264 1 |a Cham :  |b Springer International Publishing :  |b Imprint: Adis,  |c 2016. 
300 |a VIII, 181 p. 17 illus., 9 illus. in color.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
505 0 |a 1. Introduction -- 2. The Physiology and Pharmacology of Nausea and Vomiting Induced by Anti-Cancer Chemotherapy in Humans -- 3. First Generation 5HT-3 Receptor Antagonists -- 4. Second Generation Serotonin (5-HT3) Receptor Antagonist Palonosetron -- 5. The Role of Neurokinin-1 Receptor Antagonists in CINV -- 6. Olanzapine for the prevention of Chemotherapy-Induced Nausea and Vomiting -- 7. Gabapentin for the Prevention of CINV -- 8. Prevention of CINV in Patients Receiving High-Dose Multiple-Day Chemotherapy -- 9. Clinical Management of CINV -- 10. Treatment of Chemotherapy-Induced Nausea -- 11. Conclusions -- 12. Future Directions. 
520 |a This book provides a comprehensive review of new agents, a detailed description of new uses of current agents, and an integration of the available agents in clinical practice. A description of a detailed clinical approach provides clinical practitioners with the most up-to-date recommendations for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) in various clinical settings. CINV is one of the most feared treatment related toxicities. Patient surveys for the past thirty years consistently demonstrate patients’ perception of deterioration in quality of life due to chemotherapy treatments. The introduction of the antiemetics, serotonin 5-HT3 receptor antagonists and the neurokinin-1 receptor antagonists, have improved the control of chemotherapy-induced emesis, but the treatment of chemotherapy-induced nausea remains a significant clinical problem. Patients continue to have quality of life issues which prevent normal functioning during active treatment. New agents such as the second generation 5-HT3 receptor antagonist palonosetron and the new neuroknin-1 receptor antagonists rolapitant and netupitant are being introduced into clinical practice, and it is anticipated that these new agents will improve the control of CINV. Agents such as olanzapine (a FDA approved anti-psychotic), gabapentin (a FDA approved neuroleptic), and ginger (a food additive), which have been used primarily for other indications, are now being tested as potential, effective antiemetics. This work represents the first available comprehensive summary that details all new antiemetic agents and, particularly, their clinical role in treating patients; an important reference for practitioners seeking to improve the quality of life of patients undergoing chemotherapy. 
650 0 |a Medicine. 
650 0 |a Pharmacology. 
650 0 |a Oncology. 
650 0 |a Pharmacotherapy. 
650 1 4 |a Medicine & Public Health. 
650 2 4 |a Oncology. 
650 2 4 |a Pharmacology/Toxicology. 
650 2 4 |a Pharmacotherapy. 
700 1 |a Navari, Rudolph M.  |e editor. 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
776 0 8 |i Printed edition:  |z 9783319270142 
856 4 0 |u http://dx.doi.org/10.1007/978-3-319-27016-6  |z Full Text via HEAL-Link 
912 |a ZDB-2-SME 
950 |a Medicine (Springer-11650)